DPP-4 INHIBITION ATTENUATES CARDIAC DYSFUNCTION AND ADVERSE REMODELLING FOLLOWING MYOCARDIAL INFARCTION IN EXPERIMENTAL DIABETES

被引：1
|
作者：
Connelly, K. A.
Desjardins, J.
Advani, A.
Kabir, G.
Zhang, Y.
Advani, S. L.
Yuen, D. A.
Thai, K.
Gilbert, R. E.
机构：
来源：
CANADIAN JOURNAL OF CARDIOLOGY | 2011年 / 27卷 / 05期
关键词：
D O I：
10.1016/j.cjca.2011.07.597
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [1] DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes
    Connelly, Kim Alexander
    Zhang, Yanling
    Advani, Andrew
    Advani, Suzanne L.
    Thai, Kerri
    Yuen, Darren A.
    Gilbert, Richard E.
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (05) : 259 - 267
  • [2] A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4
    Yamaguchi, Takehiro
    Watanabe, Ayano
    Tanaka, Masako
    Shiota, Masayuki
    Osada-Oka, Mayuko
    Sano, Soichi
    Yoshiyama, Minoru
    Miura, Katsuyuki
    Kitajima, Shojiro
    Matsunaga, Shinji
    Tomita, Shuhei
    Iwao, Hiroshi
    Izumi, Yasukatsu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2019, 139 (02) : 112 - 119
  • [3] microRNA-21 inhibition as a treatment for preventing adverse cardiac remodelling and dysfunction following myocardial infarction
    Fernandez, I. Duran
    Ramanujam, D.
    Beck, C.
    Vaccarello, P.
    Engelhardt, S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (SUPPL 1) : S6 - S6
  • [4] Dpp-4 Inhibition Improves Cardiac Function Following Experimental Myocardial Infarction: Potential Non-glp-1 Mediated Effects
    Connelly, Kim A.
    Zhang, Yanling
    Desjardins, Jean-Francois
    Golam, Kabir
    Advani, Andrew
    Gilbert, Richard E.
    CIRCULATION, 2012, 126 (21)
  • [5] DPP-4 INHIBITION IMPROVES CARDIAC FUNCTION FOLLOWING EXPERIMENTAL MYOCARDIAL INFARCTION: POTENTIAL NON-GLP-1 MEDIATED EFFECTS
    Connelly, K. A.
    Zhang, Y.
    Advani, A.
    Advani, S. L.
    Thai, K.
    Mitchell, M.
    Kabir, G.
    Desjardins, J.
    Gilbert, R. E.
    CANADIAN JOURNAL OF CARDIOLOGY, 2012, 28 (05) : S397 - S398
  • [6] Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats
    Ikeda, Junichi
    Kimoto, Naoya
    Kitayama, Tetsuya
    Kunori, Shunji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 132 (01) : 65 - 70
  • [7] DPP-4 inhibition has beneficial effects on the heart after myocardial infarction
    Kubota, Akihiko
    Takano, Hiroyuki
    Wang, Haixiu
    Hasegawa, Hiroshi
    Tadokoro, Hiroyuki
    Hirose, Masanori
    Kobara, Yuka
    Yamada-Inagawa, Tomoko
    Komuro, Issei
    Kobayashi, Yoshio
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2016, 91 : 72 - 80
  • [8] Major adverse cardiac events with DPP-4 inhibitors
    Reactions Weekly, 2018, 1699 (1) : 7 - 7
  • [9] CARDIOMYOCYTE-SPECIFIC OVEREXPRESSION OF NOX4 ATTENUATES ADVERSE CARDIAC REMODELLING AFTER MYOCARDIAL INFARCTION
    Zhang, M.
    Looi, Y. H.
    Brewer, A. C.
    Shah, A. M.
    HEART, 2010, 96 (04)
  • [10] Acute Inhibition of Drp1 Mitigates Adverse Cardiac Remodelling following Chronic Reperfused Myocardial Infarction
    Donner, Daniel G.
    Kong, Anne M.
    Lees, Jarmon G.
    Kiriazis, Helen
    Brown, Aascha
    Tham, Yow K.
    Holien, Jessica K.
    Shen, Hsin-Hui
    Hausenloy, Derek J.
    Lim, Shiang Y.
    CARDIOVASCULAR DRUGS AND THERAPY, 2024,
12345